Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 703

Sort by

Sort Order Select

Journal Articles

How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS

Yasunobu Nagata, MD PhD, Ran Zhao, Hassan Awada, Cassandra M Kerr, MS, Abhinav Goyal, Inom Mirzaev, Sunisa Kongkiatkamon, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Jacob Scott, MD, Mikkael A. Sekeres, MD MS, Brian P. Hobbs, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1716.

https://doi.org/10.1182/blood-2019-127285

Published: 2019

Journal Articles

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Blood (2019) 134 (Supplement_1): 2999.

https://doi.org/10.1182/blood-2019-123655

Published: 2019

Journal Articles

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Mathias A. Schneeweiss, Greiner Georg, MD PhD, Susanne Herndlhofer, Julia Schellnegger, Maria-Theresa Krauth, MD, Friedrich Wimazal, MD, Corinna Steinhauser, Renate Thalhammer, MD, Ilse Schwarzinger, MD, Harald Esterbauer, MD PhD, Manuela Födinger, Peter Valent, MD, Wolfgang R. Sperr, MD

Blood (2019) 134 (Supplement_1): 4269.

https://doi.org/10.1182/blood-2019-123390

Published: 2019

Journal Articles

Prognostic Significance of Reduced BCAS4 expression in Bone Marrow Cells of Patients with Myelodysplastic Syndromes

Masayuki Shiseki, MD PhD, Mayuko Ishii, Mari Ohwashi, Kentaro Yoshinaga, MD PhD, Naoki Mori, MD PhD, Junji Tanaka, MD PhD

Blood (2019) 134 (Supplement_1): 4258.

https://doi.org/10.1182/blood-2019-124738

Published: 2019

Journal Articles

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Barry S. Skikne, MD, Anurag K. Singh, MD, Sunil Abhyankar, MD, Tara L. Lin, MD, Leyla Shune, MD, Neil Dunavin, MD, Ajoy L. Dias, MD, Brian McClune, DO, Abdulraheem Yacoub, MD, Clint Divine, Haitham Abdelhakim, MD, Siddhartha Ganguly, MD, Jennifer Hanses, Carol E Webb, BA, Joseph P. McGuirk, DO

Blood (2019) 134 (Supplement_1): 5743.

https://doi.org/10.1182/blood-2019-130828

Published: 2019

Journal Articles

Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia

Metis Hasipek, PhD, Yihong Guan, PhD, Dale Grabowski, BS, Jaroslaw P. Maciejewski, MD PhD, Hetty E. Carraway, MD MBA, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 2553.

https://doi.org/10.1182/blood-2019-130475

Published: 2019

Journal Articles

Endogenous Retinoid X Receptor Ligands Act As Tumor Suppressors in MLL-AF9 Mouse Leukemia

Orsola Di Martino, PhD, Margaret Y Ferris, MD PhD, Hadwiger Gayla, Haixia Niu, PhD, John S. Welch, MD PhD

Blood (2019) 134 (Supplement_1): 2677.

https://doi.org/10.1182/blood-2019-128869

Published: 2019

Journal Articles

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Xiaoyi Wang, MD MPH, Rong Wang, PhD, Chi Zhang, MD MPH, Amer M. Zeidan, MBBS, MHS, Nikolai A. Podoltsev, MD PhD, Scott F. Huntington, MD MPH, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD

Blood (2019) 134 (Supplement_1): 4748.

https://doi.org/10.1182/blood-2019-128821

Published: 2019

Journal Articles

Targeting Antagonists of Retinoic Acid Signaling in Acute Myeloid Leukemia

Metis Hasipek, PhD, Dale Grabowski, BS, Yihong Guan, James G Phillips, PhD, Jaroslaw P. Maciejewski, Hetty E. Carraway, MD MBA, Babal K. Jha

Blood (2018) 132 (Supplement 1): 4067.

https://doi.org/10.1182/blood-2018-99-118924

Published: 2018

Journal Articles

Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions

Amer M. Zeidan, MBBS, MHS, Weiwei Zhu, MPH, Rong Wang, PhD, Maximilian Stahl, MD, Scott F Huntington, MDMPH, Smith Giri, MBBS, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Xiaomei Ma, MD PhD, Amy J. Davidoff, PhD MS

Blood (2018) 132 (Supplement 1): 838.

https://doi.org/10.1182/blood-2018-99-116497

Published: 2018

Journal Articles

Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes

David P. Steensma, MD, Rami S. Komrokji, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Andrew M. Brunner, MD, Richard M. Stone, MD, John Barnard, PhD, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 4374.

https://doi.org/10.1182/blood-2018-99-117538

Published: 2018

Journal Articles

Lenalidomide Is Effective Treatment Option for Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis

Megan Melody, BA, MS, Najla Al Ali, M.Sc, David A Sallman, MD, Eric Padron, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD

Blood (2018) 132 (Supplement 1): 4383.

https://doi.org/10.1182/blood-2018-99-110237

Published: 2018

Journal Articles

Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach

Simona Bernardi, PhD, Camilla Zanaglio, PhD, Elif Dereli Eke, PhDStudent, Federica Cattina, MD PhD, Mirko Farina, MD, Stefania Masneri, PhD, Benedetta Rambaldi, MD, Francesca Schieppati, MD, Alessandro Turra, MD, Nicola Polverelli, MD, Enrico Morello, MD, Michele Malagola, MD, Domenico Russo, MD

Blood (2018) 132 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2018-99-109927

Published: 2018

Journal Articles

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

Blood (2018) 132 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2018-99-118070

Published: 2018

Journal Articles

Novel Fusion Genes Involving Hnrnpc and Rarg in Acute Myeloid Leukemia Mimicking Acute Promyelocytic Leukemia

Zhan Su, MD, Xin Liu, MD PhD, Yan Xu, MD, Weiyu Hu, MD, Chunting Zhao, MD, Hongguo Zhao, MD, Xianqi Feng, MD, Shuchao Zhang, Jie Yang, Xue Shi, Lugui Qiu, MD PhD, Jun Peng, MD PhD

Blood (2018) 132 (Supplement 1): 5274.

https://doi.org/10.1182/blood-2018-99-111433

Published: 2018

Journal Articles

Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome

Blood (2018) 132 (Supplement 1): 4363.

https://doi.org/10.1182/blood-2018-99-110210

Published: 2018

Journal Articles

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

David P. Steensma, Uwe Platzbecker, Koen Van Eygen, Azra Raza, MD, Valeria Santini, Ulrich Germing, MD, Patricia Font, MD, Irina Samarina, MD, Maria Díez-Campelo, Sylvain Thepot, MD, Edo Vellenga, Mrinal M. Patnaik, MDMBBS, Jun Ho Jang, MD PhD, Jacqueline Bussolari, PhD, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Pierre Fenaux

Blood (2018) 132 (Supplement 1): 463.

https://doi.org/10.1182/blood-2018-99-114877

Published: 2018

Journal Articles

A Novel Metabolic Transcriptome Identified in Myelodysplastic Syndromes (MDS) Correlates with OMS Classification and Poor Prognosis

Christophe Desterke, Estelle Balducci, Xavier Fund, Claire Borie, Annelise Bennaceur-Griscelli, MD PhD, Ali G Turhan, MD PhD

Blood (2018) 132 (Supplement 1): 5495.

https://doi.org/10.1182/blood-2018-99-110678

Published: 2018

Journal Articles

Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis

Kiran Naqvi, MD MPH, Koji Sasaki, MD, Guillermo Montalban-Bravo, MD, Michael S Teach, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2018) 132 (Supplement 1): 5513.

https://doi.org/10.1182/blood-2018-99-117266

Published: 2018

Journal Articles

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

Laura McDonald, MB MRCPI, Peter McCarthy, MB BCh BAO, Mohammad Khan, MD, Patrick Hogan, MB BCh BAO, Eileen C. Kelleher, MD, Philip Murphy, MD, John Quinn, MD PhD, Ronan Desmond, MD, Johnny McHugh, MB, FRPATH, Melanie Strickland, BNS, Mary Cahill, MD, Su Wai Maung, MRCP, MBBS, Clodagh Keohane, MD, Desmond O'Neill, MD, Daniel Ryan, MD, Vitaliy Mykytiv, MD, Helen Enright, MD

Blood (2018) 132 (Supplement 1): 5515.

https://doi.org/10.1182/blood-2018-99-113290

Published: 2018

NARROW

How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS

Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Prognostic Significance of Reduced BCAS4 expression in Bone Marrow Cells of Patients with Myelodysplastic Syndromes

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Fatty Acid Binding Protein FABP5: A Novel Therapeutic Target in Acute Myeloid Leukemia

Endogenous Retinoid X Receptor Ligands Act As Tumor Suppressors in MLL-AF9 Mouse Leukemia

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Targeting Antagonists of Retinoic Acid Signaling in Acute Myeloid Leukemia

Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions

Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes

Lenalidomide Is Effective Treatment Option for Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis

Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

Novel Fusion Genes Involving Hnrnpc and Rarg in Acute Myeloid Leukemia Mimicking Acute Promyelocytic Leukemia

Percentage of Erythroid Cells in Bone Marrow at Diagnosis As a New Prognostic Factor in Patients with Myelodysplastic Syndrome

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

A Novel Metabolic Transcriptome Identified in Myelodysplastic Syndromes (MDS) Correlates with OMS Classification and Poor Prognosis

Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only